PMV Pharmaceuticals to Engage Investors at Major Conferences
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), a leader in precision oncology, is gearing up for an exciting lineup of investor conferences. David H. Mack, Ph.D., the President and Chief Executive Officer, alongside Deepika Jalota, Pharm. D., the Chief Development Officer, will represent the company at these vital gatherings to share insights into their innovative work targeting p53.
Conference Details Set for February and March
The first of these events is the highly anticipated Oppenheimer 35th Annual Healthcare Life Sciences Conference. Scheduled for February 12, 2025, at 12:40 PM EST, this conference offers a great platform for PMV Pharma to showcase its advancements and engage with investors.
Following closely is the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. At both events, management will also be participating in one-on-one investor meetings, providing an exceptional opportunity for personalized discussions.
Access the Live Webcast
For those unable to attend in person, PMV Pharmaceuticals will provide a live audio webcast of its presentations. This webcast can be accessed online, ensuring that investors and stakeholders can stay informed about the company's progress and future prospects. Moreover, an archived replay will be offered for 90 days after the initial event.
About PMV Pharmaceuticals
PMV Pharmaceuticals is at the forefront of precision oncology, dedicated to discovering and developing small molecule therapies targeting p53, an essential protein involved in regulating cell growth and apoptosis. Notably, mutations in the TP53 gene are present in nearly half of all cancers, making PMV's mission critical in the fight against this disease.
The company was co-founded by Dr. Arnold Levine, who made groundbreaking discoveries in p53 biology dating back to 1979. His work laid the foundation for over four decades of research, which PMV continues to build on by integrating unique biological insights with a focused pharmaceutical development strategy.
Investor Relations and Media Contacts
For investors seeking more information about PMV Pharmaceuticals, Tim Smith serves as the Senior Vice President, Head of Corporate Development and Investor Relations. Direct inquiries can be sent to him via email.
Additionally, for media-related queries, Kathy Vincent from Greig Communications is available for contact. Strong communication channels ensure that both investors and the media are well-informed of PMV's ongoing developments and advancements in the precision oncology sector.
Frequently Asked Questions
What can I expect from PMV Pharmaceuticals at the upcoming conferences?
At the conferences, PMV Pharmaceuticals will present its latest developments in precision oncology, specifically regarding therapies targeting p53 mutations.
When will the conferences take place?
The conferences are scheduled for February 12, 2025, and March 4, 2025, with specific times outlined for each event.
How can I watch the presentations if I can't attend?
A live audio webcast will be available for both conferences, along with an archived replay accessible for 90 days post-event.
Who are the key representatives of PMV Pharmaceuticals at these events?
David H. Mack, Ph.D., and Deepika Jalota, Pharm. D., will represent PMV Pharmaceuticals at the conferences.
What is the focus of PMV Pharmaceuticals?
PMV Pharmaceuticals focuses on developing innovative, small molecule therapies targeting p53, aiming to improve treatment options for cancers with TP53 mutations.
